Cargando…
A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
To investigate the potential treatment evolution and outcome improvement, we retrospectively compared clinical characteristics, therapeutic strategies, treatment responses, and overall survival (OS) in patients diagnosed and treated with lymphoma-associated HLH between 2004–2012 (n = 30) and 2013–20...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584765/ https://www.ncbi.nlm.nih.gov/pubmed/34768633 http://dx.doi.org/10.3390/jcm10215114 |
_version_ | 1784597528618991616 |
---|---|
author | Lin, Cheng-Hsien Shih, Yu-Hsuan Chen, Tsung-Chih Chou, Cheng-Wei Hsu, Chiann-Yi Teng, Chieh-Lin Jerry |
author_facet | Lin, Cheng-Hsien Shih, Yu-Hsuan Chen, Tsung-Chih Chou, Cheng-Wei Hsu, Chiann-Yi Teng, Chieh-Lin Jerry |
author_sort | Lin, Cheng-Hsien |
collection | PubMed |
description | To investigate the potential treatment evolution and outcome improvement, we retrospectively compared clinical characteristics, therapeutic strategies, treatment responses, and overall survival (OS) in patients diagnosed and treated with lymphoma-associated HLH between 2004–2012 (n = 30) and 2013–2021 (n = 26). Our study showed that the clinical characteristics of lymphoma-associated HLH did not substantially change over the past two decades. However, more patients diagnosed in 2013–2021 were tested for Epstein–Barr virus than those diagnosed in 2004–2012 (69.3% vs. 33.3%; p = 0.021). In addition, Eastern Cooperative Oncology Group performance status 3–4 (hazard ratio (HR): 5.38; 95% confidence intervals (CI): 2.49–11.61; p < 0.001) and jaundice (HR: 2.91; 95% CI: 1.37–6.18; p = 0.006) were poor prognostic factors for lymphoma-associated HLH. With a comparable response rate of lymphoma treatment, patients treated in 2013–2021 had a numerically greater median OS than those treated in 2004–2012 (23.6 ± 19.8 vs. 9.7 ± 4.5 months). However, the difference was not statistically significant (p = 0.334). In conclusion, early diagnosis and tailored treatments that balance efficacy and adverse events remain the key to obtaining a better outcome in lymphoma-associated HLH. |
format | Online Article Text |
id | pubmed-8584765 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85847652021-11-12 A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve? Lin, Cheng-Hsien Shih, Yu-Hsuan Chen, Tsung-Chih Chou, Cheng-Wei Hsu, Chiann-Yi Teng, Chieh-Lin Jerry J Clin Med Article To investigate the potential treatment evolution and outcome improvement, we retrospectively compared clinical characteristics, therapeutic strategies, treatment responses, and overall survival (OS) in patients diagnosed and treated with lymphoma-associated HLH between 2004–2012 (n = 30) and 2013–2021 (n = 26). Our study showed that the clinical characteristics of lymphoma-associated HLH did not substantially change over the past two decades. However, more patients diagnosed in 2013–2021 were tested for Epstein–Barr virus than those diagnosed in 2004–2012 (69.3% vs. 33.3%; p = 0.021). In addition, Eastern Cooperative Oncology Group performance status 3–4 (hazard ratio (HR): 5.38; 95% confidence intervals (CI): 2.49–11.61; p < 0.001) and jaundice (HR: 2.91; 95% CI: 1.37–6.18; p = 0.006) were poor prognostic factors for lymphoma-associated HLH. With a comparable response rate of lymphoma treatment, patients treated in 2013–2021 had a numerically greater median OS than those treated in 2004–2012 (23.6 ± 19.8 vs. 9.7 ± 4.5 months). However, the difference was not statistically significant (p = 0.334). In conclusion, early diagnosis and tailored treatments that balance efficacy and adverse events remain the key to obtaining a better outcome in lymphoma-associated HLH. MDPI 2021-10-30 /pmc/articles/PMC8584765/ /pubmed/34768633 http://dx.doi.org/10.3390/jcm10215114 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lin, Cheng-Hsien Shih, Yu-Hsuan Chen, Tsung-Chih Chou, Cheng-Wei Hsu, Chiann-Yi Teng, Chieh-Lin Jerry A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve? |
title | A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve? |
title_full | A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve? |
title_fullStr | A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve? |
title_full_unstemmed | A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve? |
title_short | A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve? |
title_sort | decade of lymphoma-associated hemophagocytic lymphohistiocytosis: does the outcome improve? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584765/ https://www.ncbi.nlm.nih.gov/pubmed/34768633 http://dx.doi.org/10.3390/jcm10215114 |
work_keys_str_mv | AT linchenghsien adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT shihyuhsuan adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT chentsungchih adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT chouchengwei adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT hsuchiannyi adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT tengchiehlinjerry adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT linchenghsien decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT shihyuhsuan decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT chentsungchih decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT chouchengwei decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT hsuchiannyi decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT tengchiehlinjerry decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove |